Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-016074 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-03 | 2023-03-01+ | ACRS | Walker Neal | Dir | M - OptEx | — | +156.7K | 1.27M | +14% | — |
| DM | 2023-03-03 | 2023-03-02+ | ACRS | Walker Neal | Dir | S - Sale+OE | $12.50 | -59.2K | 1.27M | -4% | -$740.7K |
| DM | 2023-03-03 | 2023-03-01+ | ACRS | Walker Neal | Dir | M - OptEx | $0.00 | -156.7K | 36.5K | -81% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | M | A | 18,254 | — | 1,303,442 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Common | Common Stock | 2023-03-02 | S | D | 29,000 | $12.37 | 1,285,188 | D | — | — | (F3) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2023-03-01 | M | A | 24,000 | — | 1,314,188 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 4 | Common | Common Stock | 2023-03-01 | M | A | 18,275 | — | 1,290,188 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 5 | Common | Common Stock | 2023-03-01 | M | A | 96,150 | — | 1,271,913 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 6 | Common | Common Stock | 2023-03-03 | S | D | 30,240 | $12.63 | 1,273,202 | D | — | — | (F5) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Restricted Stock Units | 2023-03-02 | M | D | 18,254 | $0.00 | 18,254 | D | — · — to — | 18,254 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F9) The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. |
| 8 | Derivative | Restricted Stock Units | 2023-03-01 | M | D | 24,000 | $0.00 | 72,000 | D | — · — to — | 24,000 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F8) The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. |
| 9 | Derivative | Restricted Stock Units | 2023-03-01 | M | D | 96,150 | $0.00 | 0 | D | — · — to — | 96,150 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F6) The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. |
| 10 | Derivative | Restricted Stock Units | 2023-03-01 | M | D | 18,275 | $0.00 | 36,550 | D | — · — to — | 18,275 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F7) The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023. |